Julie E. Bauman

10.5k total citations · 2 hit papers
140 papers, 6.6k citations indexed

About

Julie E. Bauman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Julie E. Bauman has authored 140 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 67 papers in Pulmonary and Respiratory Medicine and 51 papers in Otorhinolaryngology. Recurrent topics in Julie E. Bauman's work include Lung Cancer Treatments and Mutations (52 papers), Head and Neck Cancer Studies (51 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Julie E. Bauman is often cited by papers focused on Lung Cancer Treatments and Mutations (52 papers), Head and Neck Cancer Studies (51 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Julie E. Bauman collaborates with scholars based in United States, Canada and United Kingdom. Julie E. Bauman's co-authors include Jennifer R. Grandis, Barbara Burtness, Vivian Wai Yan Lui, Daniel E. Johnson, C. René Leemans, Robert L. Ferris, Renato Martins, Keith D. Eaton, J.L. Geiger and William E. Gooding and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Julie E. Bauman

134 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Head and neck squamous cell carcinoma

2020 2.5k citations Daniel E. Johnson, Barbara Burtness et al. profile →
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group

2017 317 citations Shanthi Marur, Shuli Li et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Julie E. Bauman

Since Specialization

Citations

This map shows the geographic impact of Julie E. Bauman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie E. Bauman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie E. Bauman more than expected).

Fields of papers citing papers by Julie E. Bauman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie E. Bauman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie E. Bauman. The network helps show where Julie E. Bauman may publish in the future.

Co-authorship network of co-authors of Julie E. Bauman

This figure shows the co-authorship network connecting the top 25 collaborators of Julie E. Bauman. A scholar is included among the top collaborators of Julie E. Bauman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie E. Bauman. Julie E. Bauman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer 2025 ·Journal of Clinical Oncology ·Dan P. Zandberg, Lazar Vujanović, David A. Clump, Brian R. Isett, Hong Wang, Gabriel Sica, Riyue Bao, Haiyan Li, James Ohr, Heath D. Skinner, Raja R. Seethala, Simion I. Chiosea, Robert L. Ferris, Julie E. Bauman	0
2	FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab + cetuximab in pts w/ recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Julie E. Bauman, Kevin C. Allman, Robert I. Haddad	0
3	Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study 2024 ·Lung Cancer ·Dong‐Wan Kim, Byoung Chul Cho, (unknown), Sang‐We Kim, (unknown), Gee‐Chen Chang, Myung‐Ju Ahn, Rosa Álvarez, Chao‐Hua Chiu, José Trigo, Anna Estival, Sana D. Karam, (unknown), Hema Gowda, Haiyi Jiang, Julie E. Bauman	5
4	Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer 2023 ·Cancers ·Yuan James Rao, Joseph Goodman, (unknown), Julie E. Bauman	13
5	HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine 2023 ·PEDIATRICS ·Yi Zeng, Anna‐Barbara Moscicki, (unknown), Chiu‐Hsieh Hsu, Troy J. Kemp, Lígia A. Pinto, Éva Szabó, Eileen Dimond, Julie E. Bauman, Vikrant V. Sahasrabuddhe, H.‐H. Sherry Chow	7
6	Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer 2023 ·Journal of Clinical Oncology ·Julie E. Bauman, Nabil F. Saba, Denise J. Roe, Jessica R. Bauman, John M. Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, (unknown), (unknown), Conor Steuer, (unknown), Barbara Burtness, Sara Centuori, Carlos Caulı́n, Robert J. Klein, Kathylynn Saboda, (unknown), Christine H. Chung	25
7	Intensified Adjuvant Treatment for High‐Risk Resected Cutaneous Angiosarcoma of the Head and Neck 2023 ·Otolaryngology ·(unknown), Punam Thakkar, Vishal Patel, Arjun S. Joshi, Joseph Goodman, Robert D. Siegel, (unknown), (unknown), Sharad Goyal, Julie E. Bauman, Yuan James Rao	1
8	STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer 2022 ·Clinical Cancer Research ·(unknown), (unknown), Yan Zeng, Jose Rivera, Ning Cheng, (unknown), Mi‐Ok Kim, William R. Ryan, Patrick K. Ha, Julie E. Bauman, (unknown), Steven Long, Daniel E. Johnson, Jennifer R. Grandis	19
9	Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline 2022 ·Journal of Clinical Oncology ·Emrullah Yilmaz, Nofisat Ismaila, Julie E. Bauman, Raetasha Dabney, Gregory N. Gan, Richard C. Jordan, (unknown), Kedar Kirtane, Sean M. McBride, Matthew Old, Lisa M. Rooper, Nabil F. Saba, Siddharth Sheth, Rathan M. Subramaniam, Trisha M. Wise‐Draper, Deborah J. Wong, Loren K. Mell	49
10	MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors 2021 ·PLoS Pathogens ·(unknown), Rosa T. Sterk, (unknown), Joon‐Yong Chung, Kiersten L. Berggren, (unknown), (unknown), Andrew T. Cowan, Gregory N. Gan, Emrullah Yilmaz, Hanbyoul Cho, Jae‐Hoon Kim, Stephen M. Hewitt, Julie E. Bauman, Michelle A. Ozbun	25
11	A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma 2020 ·Cancer ·Sara Kochanny, Francis P. Worden, Douglas R. Adkins, Dean Lim, Julie E. Bauman, Stephanie A. Wagner, Ryan J. Brisson, Theodore Karrison, Walter M. Stadler, Everett E. Vokes, Tanguy Y. Seiwert	27
12	Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients 2019 ·Clinical Cancer Research ·Umamaheswar Duvvuri, Jonathan George, Seungwon Kim, Diego Alvarado, Veronique Neumeister, Ahmed Chenna, Richard Gedrich, Thomas Hawthorne, Theresa LaVallee, Jennifer R. Grandis, Julie E. Bauman	26
13	Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer 2018 ·Cancer Research ·Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Hua Li, Yan Zeng, Rachel A. O’Keefe, Max V. Ranall, Sourav Bandyopadhyay, Margaret Soucheray, Nevan J. Krogan, Carolyn Kemp, Umamaheswar Duvvuri, Theresa LaVallee, Daniel E. Johnson, Michelle A. Ozbun, Julie E. Bauman, Jennifer R. Grandis	31
14	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals 2017 ·Clinical Cancer Research ·Gulidanna Shayan, Benjamin Kansy, Sandra P. Gibson, Raghvendra M. Srivastava, (unknown), Julie E. Bauman, James Ohr, Seungwon Kim, Umamaheswar Duvvuri, David A. Clump, Dwight E. Heron, Jonas T. Johnson, Robert M. Hershberg, Robert L. Ferris	68
15	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group breakdown → 2017 ·Journal of Clinical Oncology ·Shanthi Marur, Shuli Li, Anthony J. Cmelak, Maura L. Gillison, Weiqiang Zhao, Robert L. Ferris, William H. Westra, Jill Gilbert, Julie E. Bauman, Lynne I. Wagner, David R. Trevarthen, (unknown), Barbara A. Murphy, Nishant Agrawal, A. Dimitrios Colevas, Christine H. Chung, Barbara Burtness	317
16	Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane 2016 ·Cancer Prevention Research ·Julie E. Bauman, Yan Zang, Malabika Sen, Changyou Li, Lin Wang, Patricia A. Egner, Jed W. Fahey, Daniel P. Normolle, Jennifer R. Grandis, Thomas W. Kensler, Daniel E. Johnson	85
17	Risk of Severe Toxicity Based on Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer 2016 ·International Journal of Radiation OncologyBiologyPhysics ·Diane C. Ling, John A. Vargo, Robert L. Ferris, James Ohr, D.A. Clump, (unknown), Umamaheswar Duvvuri, (unknown), Jonas T. Johnson, Julie E. Bauman, Barton F. Branstetter, Dwight E. Heron	0
18	Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts 2015 ·Molecular Cancer Research ·Hua Li, Sarah Wheeler, Yong-Seok Park, Zhenlin Ju, Sufi M. Thomas, Michele Fichera, Ann Marie Egloff, Vivian Wai Yan Lui, Umamaheswar Duvvuri, Julie E. Bauman, Gordon B. Mills, Jennifer R. Grandis	44
19	Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer 2014 ·Clinical Cancer Research ·Neil D. Gross, Julie E. Bauman, William E. Gooding, (unknown), Sufi M. Thomas, Lin Wang, Simion I. Chiosea, Brian L. Hood, Melanie S. Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas T. Johnson, Seungwon Kim, Athanassios Argiris, Lori J. Wirth, Marina N. Nikiforova, Jill M. Siegfried, Jennifer R. Grandis	39
20	Targeting the Transposase Domain of the DNA Repair Component Metnase to Enhance Chemotherapy 2012 ·Cancer Research ·Elizabeth A. Williamson, Leah A. Damiani, Andrei Leitão, Chelin Hu, Helen J. Hathaway, Tudor I. Oprea, Larry A. Sklar, Montaser Shaheen, Julie E. Bauman, Wei Wang, Jac A. Nickoloff, Suk‐Hee Lee, Robert Hromas	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact